Drugs in Biological Technology

ParagonRx Files with FDA REMS Panel Interim Analysis for Opioid Drugs Study

WILMINGTON, Del., July 15 /PRNewswire/ -- ParagonRx, a healthcare consulting leader in risk management and the appropriate use of drugs, has filed its interim analysis of a study that shows how its proprietary approach to risk management can help manufacturers of opioid drugs meet FDA standar...

New drugs faster from natural compounds: A UC San Diego breakthrough

Researchers have invented computational tools to decode and rapidly determine whether natural compounds collected in oceans and forests are newor if these pharmaceutically promising compounds have already been described and are therefore not patentable. This University of California, San Diego ...

Global Prescription Drugs Market to Cross $897 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on Prescription Drugs market. The global prescription drugs market is witnessing a significant deceleration in growth. Key factors slowing down growth in the global prescription drugs market include economic downturn, increasing number of...

Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August

Advisory Committee to Review Denosumab Data THOUSAND OAKS, Calif., June 22 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has asked the company to participate in a meeting of the Reproductive Health Drugs Advisory Commi...

HealthCore Responds to Need for Real-world Health Outcomes Information on Drugs and Devices with Physician Network and Prospective Effectiveness Research

WILMINGTON, Del., May 18 /PRNewswire/ -- HealthCore, Inc. is developing the Integrated Research Network (IRN(SM)) - a collaborative community of practicing physicians who participate in real-world prospective effectiveness research - in response to increasing need from industry and government to u...

NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions

- Up to $50 Million Potential Milestones plus Double Digit Royalties on Future Sales - - Company to Host Conference Call at 11:00 a.m. ET Today - EMERYVILLE, Calif., March 25 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY ), a mid-stage biopharmaceutical comp...

New label-free method tracks molecules and drugs in live cells

CAMBRIDGE, Mass. -- A new type of highly sensitive microscopy developed by researchers at Harvard University could greatly expand the limits of modern biomedical imaging, allowing scientists to track the location of minuscule metabolites and drugs in living cells and tissues without the use of any...

Osteoporosis Drugs Increase Risk for Heart Problems

Irregular Heartbeat Is Side Effect of Common Osteoporosis Medications PHILADELPHIA, Oct. 27 /PRNewswire/ -- People who take bisphosphonates for osteoporosis may be at risk for serious atrial fibrillation (AF), or irregular heartbeats, according to a new study. The research, presented at CHEST...

Pharma Opinions Site Reviews the Breakthrough Drugs of Pharmaceutical Companies

Quick glance at the latest new drugs. Pharma Opinions unveils a new site were top notch biotech companies will see their new approved products reviewed and commented. Costa de Caparica, Portugal (PRWEB) October 21, 2008 -- A new blog review on the most recent approved ...

Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board

RICHMOND, Calif., Oct. 1 /PRNewswire/ -- Lumiphore, Inc., a biotechnology leader in the development of new proprietary fluorescent metal-lanthanide technology for use in high-value applications, announced that it has signed an exclusive agreement with Biophor Diagnostics, Inc., Redwood City, C...

Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index

NEW YORK, Aug. 11 /PRNewswire/ -- Mergent, Inc., administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange Traded Funds, today announced the following change effective on the opening of trading on Thursday August 14, 2008: Biotest AG (F...

Teaching old drugs new tricks

Researchers from the European Molecular Biology Laboratory (EMBL) discovered a new way to make use of drugs' unwanted side effects. They developed a computational method that compares how similar the side effects of different drugs are and predicts how likely the drugs act on the same target molec...

Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer

Avastin Used in Combination with Taxol and Paraplatin Will Become the Clinical Gold Standard Treatment by 2011, According to a New Report from Decision Resources WALTHAM, Mass., April 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and ad...

BioDuro & The National Center for Safety Evaluation of Drugs Received Full AAALAC Accreditation

BEIJING, April 18 /PRNewswire/ -- BioDuro & The National Center for Safety Evaluation of Drugs (NCSED, the "Center") in Beijing announce their receipt of full AAALAC accreditation. BioDuro and the Center collaborate to offer preclinical toxicology and large animal DMPK for clients worldwide. ...

Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040

- Scientific Presentation at the 99th Annual Meeting of the American Association for Cancer Research (AACR) - TORONTO, April 16 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing in the research, developme...

YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING

MISSISSAUGA, ON, April 11 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI , TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that posters describing research conducted on two of its an...

Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology

NAPA, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that results of a clinical study of Pyratine-6(TM) have been featured in the Feb...

So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market

Hoffmann-La Roche Inc. CEO George Abercrombie, Pfizer R&D Head Martin Mackay, HHS Deputy Secretary Tevi Troy, Former CMS Administrator & FDA Commissioner Mark McClellan Headline Agenda at FDA/CMS Summit 2007 WASHINGTON, Nov. 15 /PRNewswire-USNewswire/ -- It's shaping up to be a record year f...

Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions

- Isis will own 18 percent of Altair and will receive milestones and royalties on antisense drugs developed by Altair - Altair to conduct clinical development of ISIS 369645 for asthma CARLSBAD, Calif. and SAN FRANCISCO, Oct. 16 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, In...

Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007

Novartis Takes Top Spot, Previously Held by GlaxoSmithKline Since June 2006 PHILADELPHIA and LONDON, Oct. 16 /PRNewswire-FirstCall/ -- Thomson Scientific, part of The Thomson Corporation (NYSE: TOC ; TSX: TOC) and leading provider of information solutions to the worldwide research and business ...

Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases

- Includes license of two antisense drugs in development targeting glucagon receptor and glucocorticoid receptor - Includes research collaboration to identify antisense drugs to inhibit additional targets to treat metabolic diseases - Conference call webcast Thursd...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

- Results from a randomized Phase IIb trial reported at 2009 ASCO Annual Meeting - MISSISSAUGA, ON, June 1 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI , TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio ...

China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs

HARBIN, China, May 26 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI ), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced that it recently obtained production appro...

ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs

FREDERICK, Md., April 29 /PRNewswire/ -- ImQuest BioSciences and Arisyn Therapeutics jointly announced today that they have entered into a strategic drug development partnership to provide support necessary to develop Arisyn's portfolio of novel inhibitors for the treatment of infectious disease a...

New Insights into the Mechanism of Action of Antipsychotic Drugs

ROCKVILLE, Md., March 10 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) reports the publication in Schizophrenia Research , the official journal of the Schizophrenia International Research Society, of a manuscript entitled "Common effect of antipsychotics on the biosynthes...

Safer nanoparticles spotlight tumors, deliver drugs

Small is promising when it comes to illuminating tiny tumors or precisely delivering drugs, but many worry about the safety of nano-scale materials. Now a team of scientists has created miniscule flakes of silicon that glow brightly, last long enough to slowly release cancer drugs, then break down...

VAP Cholesterol Test Helps In Search For New Heart Disease Drugs

Peer-reviewed journal, Science, reports that advanced cholesterol test aids in identifying connection between improved lipid profile and heart protection BIRMINGHAM, Ala., Feb. 16 /PRNewswire/ -- Using the VAP Cholesterol Test from Atherotech, Inc., University of Maryland researchers h...

China Sky One Medical, Inc. Obtains Production Rights for Nine New Drugs

HARBIN, China, Nov. 13 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI ), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it...

ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs

EXTON, Pa., July 8 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) has been informed by U.S. Food and Drug Administration (FDA) that the July 23, 2008 meeting of its Advisory Committee for Pharmaceutical Science and Clinical Pharmacology is not intended to discuss specifical...

Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs

EAST SETAUKET, N.Y., June 25 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and Lixte Biotechnology Holdings, Inc. extended their Coo...

AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs

NEW YORK, June 10 /PRNewswire-FirstCall/ -- AngioGenex Inc. (OTC Bulletin Board: AGGX.OB) a New York-based biotechnology company, and the leader in the field of Id targeted anti-angiogenic drugs, announced the appointment of William Garland PhD as Chief Executive Officer. Dr. Garland, formerly...

Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs

ARLINGTON, Va., May 7 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced that it has established an agreement ...

Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs

Harvard Medical School Researchers Used Thermo Scientific Dharmacon siRNA to Identify 273 Human Proteins Needed for Reproduction of the Virus that Causes AIDS WALTHAM, Mass., Jan. 31 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc., the world leader in serv...

Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs

- HGS acquires exclusive rights to develop and commercialize small-molecule IAP inhibitors in oncology - - Lead compound AEG40826 works synergistically with HGS TRAIL receptor antibodies to enhance anticancer activity of both drugs - - IAP inhibitors also show prom...

First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs

SAN FRANCISCO, Oct. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced preclinical data presented at the 19th annual AACR-NCI-EORTC Symposium show its bis-platinate drug candidates, CT-47613 and CT-47609, kill tumors refractory to currently marketed pl...

Tapeworm's Chemical Trick Could Make Drugs More Effective

MADISON, WI - To survive and thrive in a decidedly hostile environment, the lowly tapeworm uses a chemical trick to evade the propulsive nature of its intestinal home. Capitalizing on that tapeworm chemistry, scientists at the University of Wisconsin-Madison believe they may have found a way to ...

Why are new drugs failing?

The FDA's recent decision to pull Pfizer Cox-2 inhibitor Bextra from the marketplace clearly jolted both Pfizer and the market. Pfizer was initially caught up in the Merck Vioxx dilemma months ago and its stock has declined from $38 per share a year ago to under $25 per share in February. It has ...

Femtogram Sensitivity of the Antipsychotic Drugs Raclopride and Ritanserin Using a Varian 1200L LC/MS/MS

J. Beck and C. Schmidt Varian, Inc. Introduction Ritanserin (Tisterton) is a serotonin-2 antagonist drug shown to be effective in the treatment of anxiety and depression 1 while Raclopride acts as a dopamine D2 receptor antagonist. 2 These two compound...

Rapid Screening of Amphetamine Drugs in Urine by Positive Ion Electrospray LC/MS/MS

Z. Yang and S. Sadjadi, Varian, Inc. Introduction Amphetamine drugs are often abused and misused in sports, in the work place, and by recreational users. Forensic, clinical, and doping laboratories are frequently asked to analyze for the presence of amphetamines in ...

A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors)

Purpose In clinical research, the monitoring of protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) antiretroviral drugs is of significant interest due to the importance of assessing inter-individual and intra-individual metabolism variability. ...